| Gene Symbol | ent-gene-d289a3d6 |
| Category | Disease-Modifying Therapy |
| Target | NRF2 (NFE2L2) / KEAP1 Pathway |
| Development Stage | Phase I-II |
| Route of Administration | Oral |
| Key Compounds | Sulforaphane, Dimethyl fumarate, Bardoxolone methyl |
| Model | Finding |
| MPTP model | 40-60% dopaminergic neuron protection |
| 6-OHDA model | 35-45% neurodegeneration attenuation |
| Alpha-synuclein overexpression | Enhanced autophagic clearance of α-synuclein |
| Drosophila PD model | Extended lifespan, preserved climbing ability |
| Population | Dose |
| Early PD | 100-200 μmol/day (~17-35 mg SFN) |
| Prodromal | 40-100 μmol/day |
| Trial | Phase |
| NCT04550494 | Phase II |
| KG Connections | 2 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |